Lipoprotein(a) Guide: Risks, Testing, And New Treatments
Learn about lipoprotein(a), a genetic risk factor for heart disease and stroke.
Understanding Lipoprotein(a)
Lipoprotein(a), commonly abbreviated as Lp(a), is a spherical lipid particle that plays a significant role in cardiovascular health. Unlike many other risk factors for heart disease, Lp(a) is primarily determined by genetics and remains relatively constant throughout an individual’s lifetime. This means that your Lp(a) level is largely inherited from your parents and cannot be substantially changed through diet or exercise alone.
Lp(a) is synthesized in the liver and contains two crosslinked proteins as part of its structure: apolipoprotein(a) covalently bound to apolipoprotein B-100. While it shares some structural similarities with LDL cholesterol, Lp(a) differs in molecular weight, electrophoretic mobility, and protein-to-lipid ratio. These differences are clinically important because Lp(a) levels are not regulated by the same mechanisms that control LDL cholesterol, making it an independent and particularly important cardiovascular risk factor.
The Cardiovascular Impact of Elevated Lp(a)
Elevated Lp(a) levels are associated with significantly increased risk of atherosclerotic cardiovascular disease, including early and aggressive coronary artery disease, myocardial infarction (heart attack), and stroke. Research shows that elevated Lp(a) can nearly double the risk of atherosclerotic cardiovascular disease and aortic stenosis, and it tends to lead to disease at a younger age than in individuals with normal levels.
One of the most concerning aspects of elevated Lp(a) is that it can cause cardiovascular disease in individuals without other traditional cardiovascular risk factors. This means that someone with normal cholesterol levels, normal blood pressure, and healthy lifestyle habits may still face significant heart disease risk if they have elevated Lp(a).
Beyond coronary artery disease, elevated Lp(a) is associated with increased risk of:
- Venous thromboembolism (blood clots in veins)
- Calcific aortic stenosis (narrowing and stiffening of the aortic valve)
- Premature cardiovascular events
- Aggressive atherosclerosis progression
Normal Lp(a) Levels and Risk Categories
Understanding your Lp(a) level is crucial for assessing your cardiovascular risk. The following ranges help classify risk:
| Lp(a) Level (mg/dL) | Risk Category | Clinical Significance |
|---|---|---|
| Less than 25 | Normal | Low risk; genetics unlikely major factor |
| 25-50 | Borderline | Mild elevation; monitor with other factors |
| 50-70 | Elevated | Significant cardiovascular risk begins |
| 70-180 | High | Substantially increased risk |
| Greater than 180 | Very High | Extremely high cardiovascular risk |
According to recent estimates, approximately 64 million U.S. residents have an Lp(a) level of 60 mg/dL or higher, placing them at elevated risk. More concerning, over 3 million Americans have levels of 180 mg/dL or greater, which confers extremely high risk for cardiovascular events.
Who Should Be Tested for Lp(a)?
Screening for Lp(a) is particularly important for individuals in the following categories:
- Those with a family history of elevated Lp(a)
- Individuals with a family history of premature cardiovascular disease (heart attack or stroke before age 55 in men, age 65 in women)
- Patients with early or aggressive coronary artery disease
- People with a normal lipid profile but cardiovascular disease symptoms
- Those with aortic valve stenosis of unknown cause
- Individuals with mildly elevated cholesterol or LDL despite lifestyle modification
- Patients presenting with myocardial infarction or stroke without traditional risk factors
Despite the importance of Lp(a) testing, many patients with atherosclerotic cardiovascular disease worldwide are managed without knowledge of their Lp(a) levels. Studies indicate that over one-quarter of patients with cardiovascular disease are at heightened risk because of elevated Lp(a), yet remain untested.
Lp(a) Testing and Interpretation
Lipoprotein(a) testing is performed through a simple blood test that measures the serum level of this lipid particle. The test is straightforward to order and interpret, making it an accessible screening tool for healthcare providers.
When interpreting results, it’s important to understand that Lp(a) measurements may vary slightly between laboratories, and some laboratories report results in different units. Your healthcare provider can help you understand what your specific results mean for your individual risk profile.
The test is particularly valuable because it provides information independent of other lipid measurements. Even if your LDL cholesterol is well-controlled or your overall lipid profile appears normal, an elevated Lp(a) level suggests a need for more aggressive treatment of other modifiable risk factors and closer cardiovascular monitoring.
Limitations of Current Lp(a) Management
One of the most significant challenges in managing elevated Lp(a) has been the lack of effective treatment options. Unlike LDL cholesterol, which can be lowered through statins, other medications, diet, and exercise, Lp(a) levels are remarkably resistant to conventional interventions. Current lipid-lowering therapies have minimal to no effect on Lp(a) levels, and lifestyle modifications such as diet and exercise do not significantly reduce Lp(a).
This has led to Lp(a) being described as “one of the last untreatable frontiers of cardiovascular risk.” Historically, once a patient was found to have elevated Lp(a), there were limited therapeutic options beyond aggressive management of all other modifiable risk factors.
Emerging Treatment Options
The landscape for Lp(a) management is changing rapidly with the development of investigational therapies known collectively as nucleic acid therapeutics. These innovative treatments show unprecedented promise in reducing Lp(a) levels.
One particularly promising agent is lepodisiran, a small interfering RNA therapy. In clinical trials, a single dose of lepodisiran lowered Lp(a) to undetectable levels from day 29 to day 281 following administration, with levels remaining 94% below baseline at the end of a 48-week study. This unprecedented degree and duration of Lp(a) reduction suggests that lepodisiran could potentially be administered once or twice annually, similar to a vaccine approach.
These emerging therapies represent a major breakthrough for patients with elevated Lp(a), particularly those at very high risk for cardiovascular events. However, widespread awareness and education among healthcare providers is essential to maximize the benefits of these treatments.
Clinical Considerations for Providers
Healthcare providers need to be aware of several important clinical considerations regarding Lp(a):
- Lp(a) is a genetically determined, lifelong risk factor that cannot be changed through conventional interventions
- Elevated Lp(a) can cause premature cardiovascular disease in otherwise low-risk individuals
- Testing should be part of routine risk assessment, particularly in primary prevention settings
- Results of Lp(a) testing should guide intensity of other risk factor management
- Awareness of emerging therapies is critical for appropriate patient counseling and treatment planning
- Lp(a) levels differ among various demographic and ethnic groups, with implications for screening strategies
Global Health Implications
The prevalence and significance of elevated Lp(a) represent a substantial global health challenge. International research initiatives are helping to better understand how Lp(a) affects different populations and to identify optimal treatment strategies across diverse patient groups.
Cleveland Clinic investigators have published findings from international studies examining Lp(a) patterns across different populations, providing valuable insights into ethnic and demographic variations in Lp(a) levels and their clinical implications. These findings underscore the need for major global educational efforts to promote Lp(a) measurement in routine clinical practice worldwide.
The Future of Lp(a) Management
As new therapies for Lp(a) reduction advance through clinical trials, the therapeutic landscape for this previously untreatable risk factor is transforming. Several investigational therapies are in various stages of development, and some international trials are evaluating their safety and efficacy across diverse populations.
The emergence of effective Lp(a)-lowering therapies emphasizes the importance of identification and risk stratification. Patients who would benefit most from these new treatments are those with significantly elevated Lp(a) levels and those with strong family histories of premature cardiovascular disease. Early identification allows for timely intervention before cardiovascular events occur.
Frequently Asked Questions About Lipoprotein(a)
Q: Is lipoprotein(a) the same as LDL cholesterol?
A: No. While Lp(a) and LDL cholesterol share some structural similarities, they are distinct lipid particles. Lp(a) is genetically determined and cannot be lowered by traditional lipid-lowering therapies, whereas LDL cholesterol can be modified through diet, exercise, and medications.
Q: Can I lower my Lp(a) through diet and exercise?
A: Unfortunately, conventional lifestyle interventions have minimal to no effect on Lp(a) levels. Since Lp(a) is primarily genetically determined and remains constant throughout life, emerging pharmaceutical therapies represent the most promising approach to lowering elevated levels.
Q: How often should I have my Lp(a) levels tested?
A: Since Lp(a) levels remain relatively constant throughout life, a single test is generally sufficient for risk assessment. However, if you have elevated levels and are considering new therapies, your healthcare provider may recommend periodic testing as part of your monitoring plan.
Q: If I have elevated Lp(a), what can I do now?
A: While waiting for new therapies to become available, focus on aggressively managing all other modifiable cardiovascular risk factors, including LDL cholesterol, blood pressure, blood sugar, smoking status, and physical activity. Discuss with your healthcare provider about potential participation in clinical trials of new Lp(a)-lowering therapies.
Q: Is elevated Lp(a) hereditary?
A: Yes. Lp(a) levels are genetically determined, meaning they are inherited from your parents. If you have elevated Lp(a), your family members should also be screened, as they may carry the same genetic predisposition.
Q: Can medications like statins lower Lp(a)?
A: No. Current FDA-approved lipid-lowering therapies, including statins and other medications, have little to no effect on Lp(a) levels. This is one reason why Lp(a) has been considered one of the last untreatable frontiers of cardiovascular risk, though this is changing with emerging therapies.
References
- Lipoprotein(a): Progress on One of the Last Untreatable Frontiers of Cardiovascular Risk — Cleveland Clinic. 2024. https://consultqd.clevelandclinic.org/lipoproteina-progress-on-one-of-the-last-untreatable-frontiers-of-cardiovascular-risk
- Lipoprotein (a) in Serum — Cleveland Clinic Laboratories. 2024. https://clevelandcliniclabs.com/lipoprotein-a-in-serum/
- Lipoprotein(a) in clinical practice: What clinicians need to know — Cleveland Clinic Journal of Medicine. 2024. https://www.ccjm.org/content/92/11/679
- The Role of Lipoprotein(a) In Cardiovascular Disease — Cleveland Clinic Medical Education. 2024. https://www.clevelandclinicmeded.com/live/courses/cvprevention/
- Lipoprotein(a), High-Sensitivity C-Reactive Protein, and All-Cause Mortality — National Center for Biotechnology Information. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC12277628/
Similar Articles
Read full bio of Sneha Tete
